Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | LCK | P06239 | 5/20 | 0.38 |
| ▸ | TEK | Q02763 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 9/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | CSK | P41240 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ABL2 | P42684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30582625 | 1.00 | KCNH2 (0.39) | KCNH2LCKTEKKDRSRC | |
| SCHEMBL30582544 | 0.89 | SRC (0.44) | LCKTEKKDRSRCABL1 | |
| SCHEMBL26108026 | 0.89 | SRC (0.44) | LCKTEKKDRSRCABL1 | |
| SCHEMBL30582593 | 0.89 | KCNH2 (0.34) | KCNH2LCKTEKKDRSRC | |
| SCHEMBL30582590 | 0.89 | KCNH2 (0.34) | KCNH2LCKTEKKDRSRC | |
| SCHEMBL26108928 | 0.89 | KCNH2 (0.34) | KCNH2LCKTEKKDRSRC | |
| SCHEMBL30582602 | 0.89 | DYRK1A (0.33) | KCNH2LCKTEKKDRSRC | |
| SCHEMBL26106237 | 0.89 | DYRK1A (0.33) | KCNH2LCKTEKKDRSRC | |
| SCHEMBL30582628 | 0.88 | LCK (0.37) | KCNH2LCKTEKKDRSRC | |
| SCHEMBL26105815 | 0.88 | LCK (0.37) | KCNH2LCKTEKKDRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024091370-A1 | 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |